Summary: Wandercraft’s acquisition of Ekso Bionics combines two major medical exoskeleton companies, expanding their technology portfolios, clinical reach, and ability to provide robotic mobility solutions from rehabilitation through personal use.
Key Takeaways:
- Broader exoskeleton portfolio: Atalante X, EksoNR, Eve, and Indego Personal will span rehabilitation and everyday mobility for people with conditions including stroke, spinal cord injury, MS, and acquired brain injury.
- Greater clinical reach: The combined company will leverage Ekso’s U.S. presence and clinical experience with Wandercraft’s robotics expertise and international reach, supporting more rehabilitation centers and clinicians.
- Focus on access and coverage: Wandercraft plans to maintain all four products while expanding access, reimbursement support, and advocacy for broader coverage of personal exoskeletons.
Wandercraft has acquired Ekso Bionics Inc. from a subsidiary of ChronoScale Holdings Corporation, bringing together two companies known for robotic mobility. They contribute complementary technologies and decades of combined experience to help more people to stand, walk, and participate more fully in everyday life. According to a company statement, “Together, they form the world’s leading medical exoskeleton company, offering an unmatched combination of technology, clinical experience, and global reach.”
The acquisition combines Wandercraft’s expertise in advanced robotics and physical AI and its leadership in EMEA with Ekso Bionics’ strong U.S. presence, extensive clinical experience, and commercial reach. Both companies have been trailblazers in medical exoskeletons, driving technological innovation, R&D, and clinical research. The combination creates a broader portfolio of medical exoskeletons spanning the continuum of care, from rehabilitation to everyday personal mobility.
“We share a vision for how robotics can empower people whose mobility has been unfairly limited by injury or disease,” said Matthieu Masselin, CEO and co-founder of Wandercraft. “Both companies have pioneered advanced technologies to help people stand, walk, and participate more fully in everyday life. By bringing together our products, teams, and clinical relationships on both sides of the Atlantic, we have an exceptional opportunity to expand access to robotic mobility worldwide, reach more patients and rehabilitation professionals, and help more people experience the independence and connection that upright mobility can offer.”
Atalante X and EksoNR currently support patients in standing and walking at more than 700 rehabilitation centers worldwide. Together, these complementary platforms hold U.S. FDA clearances and CE marking covering stroke, spinal cord injury, multiple sclerosis, and acquired brain injury. For personal use, Eve brings Wandercraft’s hands-free, self-balancing technology into the home, while Indego Personal offers a modular wearable exoskeleton. Each serves eligible individuals with spinal cord injuries, providing tailored approaches to upright mobility that align with their needs and goals.
According to the company, Wandercraft intends to continue supporting all four products, as well as the customers, clinicians, and individuals who rely on them.
“Ekso has spent two decades pioneering robotic technologies, advancing engineering and R&D, and building a robust body of clinical research and evidence that has earned the trust of clinicians and the people who rely on our products,” said Scott Davis, of the go-forward Ekso Bionics. “Joining Wandercraft represents an exciting next chapter, uniting two organizations with a shared commitment to mobility, rehabilitation, and innovation. Together, we can build on that trailblazing work and expand our ability to develop and deploy technologies that make a meaningful difference for more people.”
The acquisition, according to Wandercraft, reinforces the company’s strength in expanding market access and efficiently deploying personal exoskeletons worldwide. Patients are already receiving training at the Walk in New York by Wandercraft rehabilitation center, and a dedicated access team helps users and their care teams navigate benefits, documentation, reimbursement, financing, and coordination with clinicians and payers. For individuals in the U.S. who meet eligibility and medical necessity requirements, Medicare covers qualifying personal exoskeletons under its brace benefit category, billed under HCPCS code K1007. With greater scale, the combined company has plans to advocate for broader coverage worldwide.
The combination is also expected to enhance customer service through a broader international network and shared clinical expertise. For example, rehabilitation centers can now consult specialists with expertise in both Atalante X and EksoNR to identify the best solutions for their patients while maintaining dedicated, product-specific support.
The boards of directors of Wandercraft and ChronoScale Holdings Corporation unanimously approved the transaction, which was signed and closed simultaneously. Financial terms were not disclosed.
